211At-NCS-ChiBC8

211At-NCS-ChiBC8 is a chimeric radioimmunotherapy (RIT) candidate designed to target CD45, a receptor-linked protein tyrosine phosphatase expressed on nearly all hematopoietic cells. The agent consists of the chimeric monoclonal antibody ChiBC8 (derived from the murine BC8 antibody) conjugated to the potent alpha-emitting radioisotope astatine-211 (211At) via an isothiocyanatophenethyl-ureido-closo-decaborate(2-) (B10-NCS) boron cage linker. This radiopharmaceutical is primarily investigated for use in targeted conditioning regimens prior to hematopoietic cell transplantation (HCT) for patients with hematologic malignancies, such as acute myeloid leukemia (AML). By utilizing alpha particles, which have high linear energy transfer and a short path length, 211At-NCS-ChiBC8 aims to deliver lethal radiation specifically to leukemic and immune cells while minimizing damage to surrounding healthy tissues compared to traditional beta-emitting isotopes like Iodine-131.

Other names

astatine-211-labeled chimeric BC8astatine211-labeled chimeric BC8astatine 211-labeled chimeric BC8211At-labeled ChiBC8211At-NCS-chimeric BC8